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Abstract
Background
To evaluate the additional discriminatory performance of adiponectin, leptin, and their ratio
in the identification of impaired glucose tolerance (IGT) in men and women without diabetes
on top of conventional risk factors.
Methods & results
A total of 698 subjects underwent an oral glucose tolerance test (oGTT) and adipocytokine
measurements. A comprehensive stepwise selection procedure was performed, followed
by c-statistics and integrated discrimination improvement (IDI) analysis. In males, adiponec-
tin levels were significantly lower in the IGT group compared to the non-IGT group (Whitney
U test, p < 10–4), whereas leptin levels were significantly higher (p = 0.009) in IGT group. In
females, adiponectin and leptin levels were not significantly different between groups
(Mann-Whitney U test, p = 0.073 and p = 0.08, respectively). Adjusting for the most informa-
tive, sex-specific, clinical and biochemical factors, adiponectin, leptin and their ratio were
not found to be significant predictors of the response to the glucose load, when modelled as
continuous terms or tertiles. In males, the area-under-the-curve (AUC) for adiponectin was
estimated at 0.620 (95% CI: 0.558–0.682) and the addition of adiponectin into the basic
model provided a ΔAUC benefit of 0.004, showing no additional discriminatory benefit on
top of conventional risk factors (IDI p-value: 0.27), nor did the addition of leptin or their ratio.
The results were similar in females.
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Conclusions
In Chinese individuals without diabetes, no significant evidence for the potential discrimina-
tory value of adiponectin, leptin or their ratio in the identification of IGT on top of conventional
risk factors was observed.
Introduction
Insulin resistance (IR) is closely associated with abdominal adiposity, a surrogate measure of
visceral adiposity. Adipocytes are considered to be hormonally active by releasing two pro-
teins, adiponectin and leptin. Adiponectin is thought to exert insulin-sensitizing, anti-athero-
genic and anti-inflammatory actions [1; 2] via peroxisome-proliferator receptor γ action [3].
Leptin, a protein circulating in proportion with body fat-cell stores, reflects nutritional status
and subcutaneous fat mass, information essential for the regulation of appetite and energy
expenditure by neural centres [4–6].
Interestingly, adiponectin has been found to be inversely and independently associated
with IR [7; 8] and impaired glucose tolerance (IGT) using a range of insulin sensitivity indices
[9]. A meta-analysis of prospective cohort studies confirmed that higher adiponectin concen-
trations were associated with a lower risk of type 2 diabetes mellitus (T2DM) [10]. Conversely,
leptin has been reported to have a positive correlation with IR [11]. The leptin: adiponectin
ratio has previously been suggested to be a better indicator of IR than the individual adipo-
kines [12].
Despite evidence describing the associations between adiponectin, leptin and their ratio
with risk of T2DM, evidence regarding their clinical utility is still unclear [10; 13; 14]. Most
importantly, the literature on the performance in correctly identifying subjects with glucose
tolerance status is still scarce and contradictory [15; 16]. This may be of particular concern in
terms of preventing cardiovascular disease (CVD) risk, given the role of postprandial glycae-
mia on both the onset of CVD [17] and secondary CVD prevention [18]. Moreover, ethnic
variances in adipokine have been reported and Asians may have the least favorable profile [19;
20]. Finally, it has been demonstrated in a cluster randomized trial that lifestyle intervention
programme for Chinese people with impaired glucose tolerance can reduce incidence of car-
diovascular and all-cause mortality and diabetes over a period of 23 years [21]. Therefore,
timely identification of the prediabetic state may be an issue of major public health
importance.
Thus, the present study was aimed to evaluate (1) the diagnostic performance of adiponec-
tin, leptin and their ratio in the correct classification of glucose intolerance status in men and
women using oral glucose tolerance test (oGTT) as the reference standard, and (2) whether
adipokine levels would enhance the discriminatory value of established markers in predicting
impaired glycaemic status. A positive result would be a proof of their still uncertain clinical
utility and an alternative for the poorly reproducible oGTT.
Methods
Subjects and measurements
The Guangzhou Biobank Cohort Study is an ongoing collaboration between the Guangzhou
Number 12 Hospital, Guangzhou, China, the University of Hong Kong, Hong Kong, and the
University of Birmingham, Birmingham, U.K. The Guangzhou Biobank Cohort Study–
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Cardiovascular Disease Subcohort (GBCS-CVD) consists of 1,300 participants who were
intensively phenotyped for a range of surrogate markers of vascular disease as well as coagula-
tory and inflammatory markers [22]. A random subset of the participants (n = 698) underwent
both adipokine measurement and oGTT, which was interpreted according to relevant guide-
lines [23]. Patients with known diabetes mellitus were excluded from the analysis. Those with
a normal response to glucose load, yet with impaired fasting glycaemia (IFG, fasting
glucose> 5.6 and< 7.0 mmol/L) were included in the non-IGT group for the purpose of anal-
ysis and this inclusion was then explored in sensitivity analyses. Those patients with a response
to oGTT in the non-diabetic range and with a glycated haemoglobin (HbA1c) measured in the
diabetic range (HbA1c > 6.5%) were initially included in the study group, yet subsequently
excluded in the sensitivity analyses. Detailed descriptions of the measurement methodology
can be found elsewhere [22; 24]. The Guangzhou Biobank Cohort Study was approved by
Guangzhou Medical Ethics Committee of the Chinese Medical Association, Guangzhou,
China and written informed consent was obtained from all participants.
Statistical analysis
Subject characteristics were summarised by glycaemic status, using means and standard devia-
tions, medians and inter-quartile ranges or numbers and percentages as appropriate. Normal-
ity was ascertained by visualisation and confirmed by Shapiro-Wilk test. Unadjusted odds
ratios (IGT vs. non IGT) were then computed along with 95% confidence intervals. The non-
parametric Mann-Whitney U test was also used to examine differences between the groups.
All analyses were stratified by sex.
To select important risk factors (not including adiponectin, leptin and their ratio), includ-
ing anthropometric measurements, age, parental history, lipids, inflammation markers for
adjustment we used a comprehensive stepwise selection procedure [25]. This procedure
involved selecting for possible inclusion from potential variables the subset of covariates for
which the P-value for the unadjusted odds ratio was less than 0.25. These covariates were then
included in a forward stepwise selection procedure, with P-value for addition set at�0.05 and
the P-value for removal set at�0.1. This was then complemented by carrying out a sensitivity
check, by implementing a backwards stepwise selection procedure with P-value for addition
�0.05 and P-value for removal�0.1. Any covariates which were selected for inclusion in the
backwards method but not selected in the forwards method, were then added to the model
selected using the forwards stepwise procedure and retained if their P-value was less than 0.1.
Finally, this procedure was augmented by adding any covariates not selected so far into the
model, one at a time, and retaining if their P-value was less than 0.1. All levels of categorical
variables were included if one level met the inclusion criteria. Finally, to mitigate against over
fitting, bootstrapping was then performed to reduce optimism and shrinkage estimates
reported.
The objective was to determine the prognostic value of adiponectin and leptin, in addition
to the prognostic value obtained from conventional factors (i.e. by the model selected directly
above). To this end, adiponectin and leptin, individually and jointly, and the ratio of leptin to
adiponectin, were added to the model selected above, to determine their predictive effects after
adjustment for conventional risk factors. These factors were included firstly as continuous var-
iables and then as categorical variables (tertiles) to allow for departures of non-linear effects.
Predictive performance of models was compared by computing c-statistics [area under the
curve (AUC)] and calculating the integrated discrimination improvement (IDI). The latter can
be interpreted as a difference in discrimination slopes between models (difference of mean
predicted probabilities of events and non-events) and a significant result (P-value < 0.05)
Adipokines and impaired glucose tolerance
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denotes substantial improvement [26]. Model calibration was assessed by computing the Hos-
mer and Lemeshow goodness of fit test (a P-value > 0.05 was considered indicative of an ade-
quate fit). All continuous variables were checked for normality and those for which there was
evidence of a departure from normality were transformed using an appropriate transforma-
tion. All continuous variables were then standardized onto the z-scale by subtracting the mean
and dividing by the standard deviation. This means that all OR for continuous variables can be
interpreted as increase in odds per standard deviation. No data were missing and no imputa-
tion analyses were performed. All analyses were carried out in Stata 11.2 SE.
Results
Out of 698 subjects (354 males, 344 females), one hundred ninety-six (106 males and 90
females) subjects were found to have IGT. Gender-specific sample characteristics, along with
results from univariate logistic regression analyses, are presented in Table 1. Sex-specific
AUCs for the prediction of IGT status using adiponectin, leptin or their ratio were calculated
and presented along with AUCs for other predictors and that of basic model, consisted of the
conventional predictors selected through the variable selection strategy (Table 2). Of note,
AUC for adiponectin was generally not inferior compared to the AUCs of the most informa-
tive clinical and biochemical markers in males without diabetes.
In males, adiponectin levels were significantly lower in the IGT (cases) group as compared
to the non-IGT (control) group (Whitney U test, p< 10−4), whereas leptin levels and leptin:
adiponectin ratio were significantly higher (p = 0.009 and p< 10−4 respectively) in IGT group
(Table 1). Table 3 shows that the AUC for the prediction of IGT with adiponectin was esti-
mated at 0.62 (95% CI: 0.56–0.68) in males. Table 4 shows that when modelled as a continuous
term adjusting for established conventional factors as selected from the stringent variable
selection strategy [fasting glucose, body mass index (BMI), systolic blood pressure, high-den-
sity lipoprotein (HDL)-cholesterol], adiponectin was not found to be a significant predictor of
IGT status [0.86 (0.67–1.10)]. To test for non-linear effects, adiponectin tertiles were also
examined and again found to be non-significant. Leptin, leptin:adiponectin and both adipo-
nectin and leptin also did not show any statistical significance (Table 4). The addition of adipo-
nectin essentially showed no discriminatory benefit when compared to the model consisted of
traditional markers in terms of AUC (ΔAUC = 0.004, IDI estimate: 0.003, p-value: 0.27), nei-
ther did the addition of leptin (IDI p-value: 0.18) or their ratio (IDI p-value: 0.09) (Table 3).
Sensitivity analyses (1) with the exclusion of patients with IFG and (2) with the exclusion of
those patients with HbA1c� 6.5% but with a response to oGTT in the non-diabetic range did
not alter the findings (data not shown).
In females, there was no evidence that adiponectin and leptin levels were different between
groups (Mann-Whitney U test, p = 0.073 and p = 0.08, respectively), but leptin:adiponectin
ratios differed significantly (Mann-Whitney U test, p = 0.023). Adjusting for waist:hip ratio,
fasting glucose, total cholesterol: HDL cholesterol ratio and apolipoprotein, none of the adipo-
cytokines were significant predictors of oGTT-based classification (Table 4) or conferred any
discriminatory benefit in addition to that of the basic model (Table 3). Finally, analysis using
tertiles of adiponectin, leptin or their ratio adjusting for the selected conventional factors
showed similar negative findings (Table 4). Sensitivity analyses did not alter the findings (data
not shown).
Discussion
In this cross-sectional analysis, although the AUC for adiponectin in regards to IGT prediction
was generally not inferior compared to the AUCs of the most informative clinical and
Adipokines and impaired glucose tolerance
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Table 1. Sex-specific characteristics and results from univariate and multivariate logistic regression analyses.
Non-IGT
group
IGT
group
Crude Odds Ratio
(95% CI)
Adjusted
odds
ratio
(95% CI)
Non-IGT
group
IGT
group
Crude Odds Ratio
(95% CI)
Adjusted odds ratio
(95% CI)
Males (n = 354) Females (n = 344)
N (%) 248 (70.05) 106
(29.94)
254 (73.8) 90 (26.2)
Adipocytokines
Adiponectin(μg/ml) 5.76 [6.13] 4.31
[3.20]
0.76 (0.61–0.96) 7.48
[8.78]
6.58
[6.07]
0.84 (0.68–1.05)
Leptin (ng/ml) 3.59 [4.74] 4.93
[4.87]
1.34 (1.06–1.70) 11.2
[11.81]
13.3
[9.79]
1.29 (0.93–1.81)
Leptin:Adiponectin Ratio 0.55 [1.06] 1.09
[1.34]
1.45 (1.14–1.50) 1.54
[2.70]
1.89
[2.20]
1.21 (1.01–1.45)
Anthropometric data
Body mass index (kg/m2) 22.6 [3.66] 24.3
[3.52]
1.72 (1.34–2.19) 1.47 (1.05–
2.04)
23.0
[3.64]
23.8
[3.77]
1.31 (1.02–1.67)
Waist(cm) 78.5 [11.0] 84.0
[11.0]
1.70 (1.33–2.17) 74.0
[10.0]
78.0
[10.0]
1.50 (1.17–1.92)
Waist:hip ratio 0.89 [0.08] 0.91
[0.06]
1.56 (1.22–1.99) 0.82
[0.08]
0.85
[0.10]
1.65(1.26–2.17) 1.49 (1.07–2.08)
Glucose and insulin
Haemoglobin A1c (%) 5.90 [0.50] 6.0 [0.60] 1.35 (1.04–1.76) 5.81 [0.4] 6.0 [0.50] 1.58 (1.19–2.10)
Glucose at 0h(mmol/L) 5.11 [0.60] 5.54
[0.70]
1.67 (1.29–2.17) 3.36 (1.62–
6.95)
5.02
[0.52]
5.40
[0.58]
1.82 (1.40–2.37) 3.65 (2.33–5.74)
Glucose at 2h(mmol/L) 6.23 [1.64] 9.12
[1.31]
6.34 [1.3] 8.59
[1.14]
Insulin at 0h(mU/L) 4.54 [4.05] 6.18
[5.81]
1.74 (1.16–2.60) 5.84
[3.89]
7.02
[5.73]
1.17 (0.87–1.58)
Insulin at 2h(mU/L) 16.2 [17.6] 32.7
[36.2]
19.6
[17.8]
36.6
[43.2]
HOMA-IR 1.05 [0.99] 1.41
[1.47]
1.91 (1.24–2.97) 1.34
[1.04]
1.79 [1.4] 1.22 (0.89–1.67)
Lipids
Triglycerides (mmol/L) 1.35 [0.98] 1.70
[1.14]
1.41 (1.12–1.77) 1.2 [0.75] 1.54
[1.02]
1.37 (1.08–1.75)
LDL(mmol/L) 3.11 [0.84] 3.19
[0.57]
1.02 (0.81–1.28) 3.43
[0.96]
3.54
[0.56]
1.11 (0.87–1.41)
HDL(mmol/L) 1.39 [0.43] 1.27
[0.38]
0.66 (0.52–0.85) 0.70 (0.50–
0.97)
1.71
[0.52]
1.64
[0.45]
0.84 (0.65–1.08)
Total cholesterol (mmol/
L)
5.44 [1.32] 5.41
[1.26]
0.98 (0.78–1.23) 5.91
[1.35]
6.22
[1.42]
1.76 (0.51–6.09)
TCHDL ratio 3.80 [1.26] 4.30
[1.48]
1.44 (1.14–1.82) 3.48
[1.32]
3.73
[1.34]
1.19 (0.93–1.52) 0.60 (0.37–0.95)
Apolipoprotein B (mmol/
L)
0.94 [0.36] 0.99
[0.33]
1.10 (0.88–1.38) 1.03
[0.39]
1.07
[0.43]
1.33 (1.03–1.72) 2.13 (1.31–3.47)
Inflammation markers
hsCRP(mg/L) 1.26 [2.3] 1.49
[2.11]
1.15 (0.95–1.40) 0.97
[2.25]
1.79
[2.54]
1.43 (1.10–1.82)
PAI-1(ng/ml) 179 [179] 194 [162] 1.14 (0.87–1.49) 144 [137] 187 [172] 1.22 (0.88–1.70)
Interleukin-6 (ng/ml) 19.7 [10.9] 20.0
[12.9]
0.85 (0.63–1.17) 18.2
[12.65]
20 [9.85] 1.03 (0.81–1.31)
Others
Age(years) 61.0 [9.0] 61.5 [9.0] 1.14 (0.91–1.42) 54.0 [4.0] 55.0 [6.0] 1.33 (1.06–1.68)
(Continued)
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biochemical markers in males non-diabetics, it was rather modest (0.62) and the inclusion of
adiponectin did not have discernible benefit over that of the conventional risk factors. Further-
more, there was no evidence to suggest that adiponectin, leptin or their ratio were significant
predictors of the response to the oral glucose load. They showed no substantial discriminatory
value in identifying IGT in subjects without diabetes when conventional predictors were taken
into account. This finding was robust in all analyses, either when the adipocytokines were
Table 1. (Continued)
Non-IGT
group
IGT
group
Crude Odds Ratio
(95% CI)
Adjusted
odds
ratio
(95% CI)
Non-IGT
group
IGT
group
Crude Odds Ratio
(95% CI)
Adjusted odds ratio
(95% CI)
Males (n = 354) Females (n = 344)
Aspartate
aminotansferase
24.1 [8.03] 24.0
[8.70]
0.86 (0.81–1.28) 23.4
[6.75]
23.4
[7.65]
1. 19 (0.50–2.85)
Alanine aminotansferase 21.0 [13.3] 24.8
[15.5]
1.35 (1.07–1.70) 18.4
[10.8]
21.1
[12.3]
1.21(0.81–1.31)
SBP(mmHg) 123 [26.7] 132
[23.8]
1.54 (1.21–1.95) 1.47 (1.02–
1.91)
116 [26.7] 126
[27.3]
1.80 (1.38–2.34) 1.76 (1.28–2.43)
DBP(mmHg) 73.0 [13.6] 76.0
[13.3]
1.45 (1.14–1.83) 69.5 [16] 73.5
[13.5]
15.1 (1.16–1.93)
Parental history of
diabetes (%)
7 (3.6) 7 (6.6) 1.64 (0.61–4.42) 25 (11.7) 9 (10.1) 0.84 (0.38–1.89)
Physical activity (%) 107 (55.4) 55 (53.9) 0.94 (0.60–1.62) 140 (67.0) 56 (64) 1.01 (0.69–1.48)
Variables are presented as median [interquartile range] or as N (%). All odds ratios for continuous variables should be interpreted as increase in odds per standard
deviation. Subjects were designated with physical activity if they were classified into the high category was on the basis of International Physical Activity Questionnaires
(IPAQ).
CI: Confidence interval, DBP: Diastolic blood pressure, HDL: High-density lipoprotein, HOMA-IR: Homeostasis model assessment–insulin resistance, hsCRP: high-
sensitive C- reactive protein, IGT: Impaired glucose tolerance, LDL: Low-density lipoprotein, PAI-1: Plasminogen activator inhibitor -1, SBP: Systolic blood pressure,
TCHDL ratio: Total cholesterol-to-high-density lipoprotein ratio
https://doi.org/10.1371/journal.pone.0206964.t001
Table 2. Areas under the curve (AUC) and 95% confidence intervals (CIs) from receiver-operator characteristics (ROC) analysis for the prediction of impaired glu-
cose tolerance (conventional predictors).
AUC 95% CI AUC 95% CI
Males Females
Adiponectin 0.620 0.558–0.682 0.436 0.369–0.503
Leptin 0.587 0.524–0.650 0.562 0.496–0.627
Leptin:Adiponectin 0.633 0.571–0.695 0.580 0.517–0.644
BMI 0.653 0.592–0.714 0.589 0.521–0.657
Waist 0.646 0.585–0.707 0.618 0.552–0.683
Glucose at 0h 0.664 0.602–0.725 0.663 0.597–0.728
Insulin at 0h 0.641 0.573–0.709 0.565 0.488–0.642
HbA1c 0.585 0.519–0.651 0.622 0.553–0.691
Triglycerides 0.602 0.544–0.669 0.604 0.534–0.673
HDL 0.628 0.565–0.691 0.460 0.392–0.528
ALT 0.588 0.523–0.653 0.564 0.498–0.631
SBP 0.636 0.575–0.697 0.657 0.591–0.772
Parental history of diabetes mellitus 0.512 0.446–0.579 0.493 0.457–0.531
https://doi.org/10.1371/journal.pone.0206964.t002
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analysed as continuous variables or in tertiles. Of note, this study was not design to assess the
predictive ability of adipocytokines in the subsequent development of T2DM.
The pathophysiology underlying the previously reported association in the literature is not
fully elucidated [27]. It appears that adiponectin improves insulin sensitivity by increasing
fatty acid oxidation in muscle, and affects glucose homeostasis by suppressing hepatic glucose
production [1]. In addition to these peripheral actions, adiponectin might have direct effects
on beta cells and thus could be considered as a positive, dual regulator of both insulin sensitiv-
ity and secretion [5]. Moreover, the pattern of sex differences, the so-called “sexual dimor-
phism” in adiponectin, which might be explained on the basis of different fat amount and the
influences of sex hormones [28], was also observed in the present study and generally in the lit-
erature [29; 30]. Failure of leptin to demonstrate discriminative power in IGT prediction may
be explained, in part, by the observation that the effects of leptin on glucose metabolism are
Table 3. Areas under the curve (AUC) and 95% confidence intervals (CIs) from receiver-operator characteristics (ROC) analysis for the prediction of impaired glu-
cose tolerance.
AUC 95% CI IDI estimates IDI p-value
Males
Basic model 0.728 0.671–0.786 n/a n/a
Basic model + Adiponectin 0.731 0.674–0.789 0.00333 0.27
Basic model + Leptin 0.731 0.673–0.789 0.00301 0.18
Basic model + Leptin:Adiponectin 0.729 0.671–0.786 0.00017 0.09
Basic model + Adiponectin + Leptin 0.734 0.676–0.791 0.00634 0.90
Females
Basic model 0.756 0.697–0.816 n/a n/a
Basic model + Adiponectin 0.760 0.701–0.819 0.00374 0.28
Basic model + Leptin 0.756 0.697–0.816 0.00123 0.53
Basic model + Leptin:Adiponectin 0.758 0.699–0.818 0.00095 0.59
Basic model + Adiponectin + Leptin 0.761 0.702–0.820 0.00415 0.19
The basic Model was constructed using the variables: Glucose, body mass index (BMI), systolic blood pressure (SBP), high-density lipoprotein (HDL) for males and
waist:hip ratio, Glucose, SBP, apolipoprotein B and total cholesterol:hdl ratio for females. Each Area-under-the-Curve (AUC) was compared to that of the basic models.
ALT: Alanine aminotansferase, CI: Confidence interval, Exp: Exponential, HbA1c: Haemoglobin A1c, IDI: Integrated Discrimination Improvement
https://doi.org/10.1371/journal.pone.0206964.t003
Table 4. Sex-specific odds ratios and 95% confidence intervals (CIs) for impaired glucose tolerance prediction according to adipocytokine levels adjusting for con-
ventional factors.
Continuous term T1 T2 T3
Adiponectin
Males 0.86 (0.67–1.10) 1.76 (0.90–3.41) 1.64 (0.86–3.16) reference
Females 0.85 (0.63–1.14) 1.18 (0.59–2.38) 1.56 (0. 79–3.09) reference
Leptin
Males 0.89 (0.65–1.21) reference 1.03 (0.54–1.96) 0.76 (0.37–1.56)
Females 0.90 (0.66–1.22) reference 1.39 (0.71–2.76) 0.74 (0.36–1.52)
Leptin:Adiponectin ratio
Males 1.08 (0.80–1.45) reference 1.49 (0.76–2.91) 1.65 (0.79–3.47)
Females 1.10 (0.82–1.46) reference 2.11 (1.06–4.19) 1.26 (0.62–2.57)
The basic model (conventional factors) was constructed using the variables fasting glucose (Glu), body mass index (BMI), systolic blood pressure (sbp), high density
lipoprotein (HDL) for males and waist:hip ratio, Glu, sbp, apolipoprotein B and total cholesterol:hdl ratio for females
Adip:Adiponectin, Lept: Leptin, T: Tertile
https://doi.org/10.1371/journal.pone.0206964.t004
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much less pronounced in human skeletal muscle compared with results from animal studies
and by the hypothesis that in humans, leptin may hold a rather regulatory than instant-acting
role in the “adipoinsular axis” [6]. Impaired fasting glycaemia is a rather multifaceted condi-
tion, a global indicator of suboptimal glucose handling, potentially reflecting several different
underlying pathophysiologies, ranging from decreased beta-cell mass to insulin resistance or
genetic defects. Thus, another potential explanation for the negative findings is the heteroge-
neous nature of the condition.
People with IGT represent an asymptomatic subpopulation with increased CVD risk [31]
and there is evidence to suggest that increased risk for CVD observed in IGT is due, at least in
part, to lower-than-normal levels of adiponectin [27; 32]. Ko et al investigated the discrimina-
tory performance of adiponectin jointly with waist circumference in middle-aged males [15];
yet, that analysis did not include females or leptin. Also, ROC analysis was reported only for
diabetes prediction [AUC = 0.642) and not for IGT and most importantly, potentially impor-
tant confounders such as fasting glucose, insulin, HbA1c or inflammation markers were not
taken into consideration. Wu et al also provided an evaluation of the discriminatory ability of
several biomarkers, including adiponectin (AUC = 0.64 for diabetes prediction), using a
weighted biomarker risk score [14]; however, the analysis did not account for fasting glucose,
insulin and HbA1c, and an oGTT was not performed. Kolberg et al provided an elegant assess-
ment of the discriminatory ability of six selected biomarkers, including adiponectin, for the
prediction of diabetes, but they did not include IGT as an outcome [13].
The present study had several limitations. First, high-molecular weight (HMW) adiponec-
tin, the “active” adiponectin, was not investigated, preventing the confirmation of the reported
lack of the oGTT-induced transient decrease in HMW adiponectin in subjects with IGT [33].
Secondly, it should be noted that 84 subjects with IFG (46 males and 38 females) were included
into the normal glucose tolerance group. This decision was based on the distinct aetiologies
between IGT and IFG [34], the essentially differential roles of incretin hormones and insulin
action [35] and the disparate pattern of HMW adiponectin response to an oral glucose load
[33]. However, exclusion of these subjects did not change the results.
In summary, the role of adipocytokines in the detection of IGT was explored in a well char-
acterized group of Chinese individuals without diabetes. Through a detailed analysis adjusting
for multiple potential confounders, no significant evidence for their potential discriminatory
value in addition to conventional risk factors in the identification of IGT was observed.
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